TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Svea Vaccin AB
Closing information (x1000 SEK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
200,780
|
169,152
|
233,868 |
| Financial expenses |
56
|
0
|
41 |
| Earnings before taxes |
16,556
|
18,750
|
51,835 |
| EBITDA |
16,789
|
18,033
|
52,110 |
| Total assets |
46,228
|
37,262
|
66,383 |
| Current assets |
42,835
|
33,969
|
63,610 |
| Current liabilities |
26,923
|
20,763
|
24,826 |
| Equity capital |
17,545
|
15,509
|
41,557 |
| - share capital |
100
|
100
|
100 |
| Employees (average) |
91
|
65
|
80 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
38.0%
|
41.6%
|
62.6% |
| Turnover per employee |
2,206
|
2,602
|
2,923 |
| Profit as a percentage of turnover |
8.2%
|
11.1%
|
22.2% |
| Return on assets (ROA) |
35.9%
|
50.3%
|
78.1% |
| Current ratio |
159.1%
|
163.6%
|
256.2% |
| Return on equity (ROE) |
94.4%
|
120.9%
|
124.7% |
| Change turnover |
31,628
|
-64,716
|
124,829 |
| Change turnover % |
19%
|
-28%
|
114% |
| Chg. No. of employees |
26
|
-15
|
31 |
| Chg. No. of employees % |
40%
|
-19%
|
63% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.